Optimizing CAR-T treatment: A T²EVOLVE guide to raw and starting material selection.

ABSTRACT: Chimeric antigen receptor (CAR)-T cell products, classified as Advanced Therapy Medicinal Products (ATMPs), have shown promising outcomes in cancer immunotherapy. The quality of raw and starting materials used in manufacturing is critical to ensure the efficacy and safety of CAR-T cell products and depends primarily on the selection of the right materials and the right suppliers. It is essential to consider a long-term strategy when selecting raw and starting materials to prevent delays in the supply of innovative, high-quality, and safe therapies to patients. A thorough assessment will allow developers not only to select suppliers who comply with regulatory requirements but also to ensure a sustainable supply of materials throughout the development and the commercial phases. A careful sel

SUBMITTER: Navarro S 

PROVIDER: S-EPMC11897765 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature